{"id":"https://genegraph.clinicalgenome.org/r/5c1dac9c-6175-4102-9be8-557d5c08a3a0v1.1","type":"EvidenceStrengthAssertion","dc:description":"The relationship between the SGSH gene and mucopolysaccharidosis type IIIA (MPS IIIA), an autosomal recessive lysosomal storage disorder, was evaluated using the ClinGen Clinical Validity Framework as of April 30, 2022. SGSH encodes N-sulfoglucosamine sulfohydrolase, a lysosomal enzyme that involved in the degradation of heparan sulfate, through catalyzing the release of the sulfate groups linked to the amino group of glucosamine (PMID: 7493035). SGSH deficiency, which is present among individuals with MPS type IIIA, leads to accumulation of incompletely degraded oligosaccharides in lysosomes in the brain and other tissues, resulting in neurodegeneration with variable extra-neurologic manifestations (PMID: 18392742) \n\nThe disease mechanism of MPS IIIA is loss of function. MPS IIIA was first reported in 1971 (PMID: 4252428) and the first report of biallelic variants in SGSH among patients with MPS IIIA was published in 1995 (PMID: 7493035). Since then, at least 68 unique variants have been identified (PMID: 11668611). Both case-level (genetic) and experimental evidence support the relationship between MPS IIIA and SGSH. Reported causal variants include missense, nonsense, frameshift, and splice-altering variants. In total, 10 variants from five probands in five publications were curated (PMID: 9158154, PMID: 21671382, PMID: 15146460, PMID: 27590925, PMID: 11343308); although there is additional published case-level evidence available, the maximum score for genetic evidence (12 points) has already been reached. \n\nExperimental evidence for the relationship between SGHS and MPS IIIA includes the biochemical function of the gene product (the MPS IIIA enzyme) being consistent with the clinical and biochemical findings identified individuals with MPS IIIA (PMID: 7493035, PMID: 18392742), the biochemical and clinical features of a mouse animal model homozygous for the p.D31N variant (PMID: 11181566, PMID: 15698885, PMID: 17913701), and the impact of hematopoietic stem cell transplant therapy in a MPS IIIA mouse model (PMID: 22547151). Additional experimental evidence is available, but the maximum score for experimental evidence (6 points) has already been reached.\n\nIn sum, SGSH is definitively associated with MPS type IIIA. The association has been repeatedly demonstrated in both clinical and research settings, and has been upheld over time. ","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/5c1dac9c-6175-4102-9be8-557d5c08a3a0","GCISnapshot":"https://genegraph.clinicalgenome.org/r/438dab6d-abf4-44e8-a176-bb39ae128052","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/438dab6d-abf4-44e8-a176-bb39ae128052_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10110","date":"2022-06-15T16:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/438dab6d-abf4-44e8-a176-bb39ae128052_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10110","date":"2022-07-13T16:47:02.490Z","role":"Publisher"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/438dab6d-abf4-44e8-a176-bb39ae128052_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/438dab6d-abf4-44e8-a176-bb39ae128052_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/30c39aa6-a39a-4842-a60c-84f04296f6df","type":"EvidenceLine","dc:description":"Per ClinGen LD GCEP guidelines, gene products that have a well-established function in a metabolic pathway, supported by multiple studies over many years, and discussed in review papers are scored 2 points","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c835d214-ba67-4355-94ca-85cfea831a5a","type":"Finding","dc:description":"SGSH deficiency, which is present among individuals with MPS type IIIA, leads to accumulation of incompletely degraded oligosaccharides in lysosomes in the brain and other tissues, resulting in neurodegeneration with variable extra-neurologic manifestations (PMID: 18392742) ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/7493035","rdfs:label":"SGSH encodes N-sulfoglucosamine sulfohydrolase","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/438dab6d-abf4-44e8-a176-bb39ae128052_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0de48497-d543-48eb-96ae-ea995ec5c976","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/33e38617-b276-4705-a37b-ebda6ea79e8a","type":"Finding","dc:description":"Gene therapy results in 10% of normal brain enzyme activity and near-normalization of brain HS and GM2 gangliosides, reduced neuroinflammation and improved behavior","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22547151","rdfs:label":"Gene therapy in MPS type IIIA mouse model ","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityNonHumanRescueCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/62030269-1640-4227-9f46-e9fd9d6f06c2","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/436a7045-5937-474c-88d0-c2b8ab2fc189","type":"Finding","dc:description":"MPS type IIIA mouse model recapitulates disease phenotype, including demonstrating hepatosplenomegaly, elevated urinary GAGs, neurologic/neuropathologic anomalies, and deficient N-sulfoglucosamine sulfohydrolase enzymatic activity","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11181566","rdfs:label":"MPS type IIIA mouse model ","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6},{"id":"https://genegraph.clinicalgenome.org/r/438dab6d-abf4-44e8-a176-bb39ae128052_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/96ad347d-da1c-46cf-882e-7abecc2761d6_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/96ad347d-da1c-46cf-882e-7abecc2761d6","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27590925","rdfs:label":"MPS-02","allele":[{"id":"https://genegraph.clinicalgenome.org/r/3745f3ca-1d0a-4e51-ad57-61caf00743bc","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000199.5(SGSH):c.1080del (p.Val361fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA8817678"}},{"id":"https://genegraph.clinicalgenome.org/r/3aad6232-5678-4c94-81e7-39bacb8d1ce6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000199.5(SGSH):c.364G>A (p.Gly122Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA8818041"}}],"previousTesting":true,"previousTestingDescription":"Enzymatic activity for subjects said to be substantially reduced or non-detectable","sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/118848dd-9fab-483d-a338-c72ee2366ced_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27590925","allele":{"id":"https://genegraph.clinicalgenome.org/r/3aad6232-5678-4c94-81e7-39bacb8d1ce6"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/634c1847-11cf-45c5-ae95-628562d71dca_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27590925","allele":{"id":"https://genegraph.clinicalgenome.org/r/3745f3ca-1d0a-4e51-ad57-61caf00743bc"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]},{"id":"https://genegraph.clinicalgenome.org/r/118848dd-9fab-483d-a338-c72ee2366ced","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/118848dd-9fab-483d-a338-c72ee2366ced_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/118848dd-9fab-483d-a338-c72ee2366ced_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"PMID: 10727844: expression of p.Gly122Arg mutant in COS cells (transfected with the mutant) resulted in undetectable enzyme activity ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/634c1847-11cf-45c5-ae95-628562d71dca","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/634c1847-11cf-45c5-ae95-628562d71dca_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/634c1847-11cf-45c5-ae95-628562d71dca_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"PMID: 15542396: Sf9 insect cells transfected with the mutant shown non-detectable enzymatic activity ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2.5},{"id":"https://genegraph.clinicalgenome.org/r/05fc8983-5b43-45a7-8548-b25d492878ef_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/05fc8983-5b43-45a7-8548-b25d492878ef","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9158154","rdfs:label":"Patient 3469","allele":[{"id":"https://genegraph.clinicalgenome.org/r/f76d4b4d-fded-4d95-9604-004b53b0c1e3","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"SGSH, 11-BP DEL, NT1284","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/5116"}},{"id":"https://genegraph.clinicalgenome.org/r/9cceccce-e8d7-43aa-bb62-a6e675802215","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000199.5(SGSH):c.734G>A (p.Arg245His)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA117257"}}],"detectionMethod":"PCR and sequencing of cDNA ","firstTestingMethod":"PCR","previousTesting":true,"previousTestingDescription":"diagnosed with MPS IIIA on basis on deficient N-sulphoglucosamine sulphohydrolase enzymatic activity in cultured fibroblasts (exact level not noted)","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":[{"id":"https://genegraph.clinicalgenome.org/r/70bb4428-2d21-4bb9-9085-c718a951990a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9158154","allele":{"id":"https://genegraph.clinicalgenome.org/r/f76d4b4d-fded-4d95-9604-004b53b0c1e3"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/aae631df-f10c-4c29-bbea-0f582bab962a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9158154","allele":{"id":"https://genegraph.clinicalgenome.org/r/9cceccce-e8d7-43aa-bb62-a6e675802215"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]},{"id":"https://genegraph.clinicalgenome.org/r/aae631df-f10c-4c29-bbea-0f582bab962a","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/aae631df-f10c-4c29-bbea-0f582bab962a_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/aae631df-f10c-4c29-bbea-0f582bab962a_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"PMID: 10601282: supporting experimental data - recombinant human enzyme, p.R245H variant results in 0.05% of wild-type expression and 83% of wild-type enzyme activity in CHO cells; hypothesized to cause disease via rapid degradation of mutant enzyme (vs reduced enzyme activity)","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/70bb4428-2d21-4bb9-9085-c718a951990a","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/70bb4428-2d21-4bb9-9085-c718a951990a_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/70bb4428-2d21-4bb9-9085-c718a951990a_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Experimental data: chinese hamster ovary (CHO) cells and human fibroblasts transfected with the variant respectively show 1% and non-detectable enzyme activity (PMID: 7493035)","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2.5},{"id":"https://genegraph.clinicalgenome.org/r/0be94814-78f6-4010-a38c-59d55a615b3b_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0be94814-78f6-4010-a38c-59d55a615b3b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21671382","rdfs:label":"Patient 16","allele":[{"id":"https://genegraph.clinicalgenome.org/r/59ea8b67-8bd9-4145-abc8-0356dfcd3816","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000199.5(SGSH):c.892T>C (p.Ser298Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA129225"}},{"id":"https://genegraph.clinicalgenome.org/r/e8a34cb0-1b78-4895-8a56-c298db895318","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000017.11:g.80212070C>G (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA401359601"}}],"firstTestingMethod":"PCR","previousTesting":true,"previousTestingDescription":"Clinically diagnosed with MPS type IIIA on basis of enzyme activity (exact level unspecified)","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/d6ef8885-b268-4433-8dcb-07b968f01370_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21671382","allele":{"id":"https://genegraph.clinicalgenome.org/r/59ea8b67-8bd9-4145-abc8-0356dfcd3816"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/b955338e-9b59-4b60-bc3c-cb50e1566d6d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21671382","allele":{"id":"https://genegraph.clinicalgenome.org/r/e8a34cb0-1b78-4895-8a56-c298db895318"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]},{"id":"https://genegraph.clinicalgenome.org/r/b955338e-9b59-4b60-bc3c-cb50e1566d6d","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b955338e-9b59-4b60-bc3c-cb50e1566d6d_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/d6ef8885-b268-4433-8dcb-07b968f01370","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d6ef8885-b268-4433-8dcb-07b968f01370_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/d6ef8885-b268-4433-8dcb-07b968f01370_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"PMID: 18407553: BHK cells transfected with the p.Ser298Pro variant show 2.3% of wild-type enzyme activity and reduced enzyme expression, shown to reflect increased proteosomal degradation of the mutant enzyme","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2.0},{"id":"https://genegraph.clinicalgenome.org/r/aaae10e0-f3ba-4763-8dc1-58e07b895a98_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/aaae10e0-f3ba-4763-8dc1-58e07b895a98","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15146460","rdfs:label":"Patient A","allele":[{"id":"https://genegraph.clinicalgenome.org/r/b8b57c4f-d12b-4e03-9190-961f1c496536","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000199.5(SGSH):c.220C>T (p.Arg74Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA117258"}},{"id":"https://genegraph.clinicalgenome.org/r/0b212cfb-39e6-4f85-8e71-1f6ee3a5c460","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000199.5(SGSH):c.697C>T (p.Arg233Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA8817835"}}],"firstTestingMethod":"PCR","previousTesting":true,"previousTestingDescription":"Clinically diagnosed with MPS type IIIA, enzyme activity levels not specified ","secondTestingMethod":"SSCP","sex":"UnknownEthnicity","variant":[{"id":"https://genegraph.clinicalgenome.org/r/78fbb41c-05cd-431b-8dd8-69c4b597c8d2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15146460","allele":{"id":"https://genegraph.clinicalgenome.org/r/b8b57c4f-d12b-4e03-9190-961f1c496536"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/7483d11a-9e9c-46ad-9b56-7f4c976140e0_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15146460","allele":{"id":"https://genegraph.clinicalgenome.org/r/0b212cfb-39e6-4f85-8e71-1f6ee3a5c460"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]},{"id":"https://genegraph.clinicalgenome.org/r/7483d11a-9e9c-46ad-9b56-7f4c976140e0","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7483d11a-9e9c-46ad-9b56-7f4c976140e0_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/7483d11a-9e9c-46ad-9b56-7f4c976140e0_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"PMID: 15146460: CHO cells transfected with p.Arg233* mutant showed non-detectable enzymatic activity and non-detectable expression of the enzyme","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/78fbb41c-05cd-431b-8dd8-69c4b597c8d2","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/78fbb41c-05cd-431b-8dd8-69c4b597c8d2_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/78fbb41c-05cd-431b-8dd8-69c4b597c8d2_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"PMID: 15146460: CHO cells transfected with p.Arg74Cys mutant showed non-detectable enzymatic activity and the encoded protein showed decreased stability","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2.5},{"id":"https://genegraph.clinicalgenome.org/r/c29958ad-48a9-4cad-a040-d3cc0f94103f_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c29958ad-48a9-4cad-a040-d3cc0f94103f","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11343308","rdfs:label":"Patient SFA-17","allele":[{"id":"https://genegraph.clinicalgenome.org/r/6f91622c-353a-4dd4-b365-045fceff597e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000199.5(SGSH):c.1027dup (p.Leu343fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA203558"}},{"id":"https://genegraph.clinicalgenome.org/r/ab63ac41-8839-4be4-af0b-1023667164c5","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000199.5(SGSH):c.197C>G (p.Ser66Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA117261"}}],"firstTestingMethod":"PCR","previousTesting":true,"previousTestingDescription":"enzyme activity 0.1% vs wild-type","secondTestingMethod":"SSCP","sex":"UnknownEthnicity","variant":[{"id":"https://genegraph.clinicalgenome.org/r/ef1c54b2-97d4-4e57-bab9-6e196cdb5a8e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11343308","allele":{"id":"https://genegraph.clinicalgenome.org/r/ab63ac41-8839-4be4-af0b-1023667164c5"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/138ba925-6006-45bb-8f70-5b5a18a25fcd_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11343308","allele":{"id":"https://genegraph.clinicalgenome.org/r/6f91622c-353a-4dd4-b365-045fceff597e"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]},{"id":"https://genegraph.clinicalgenome.org/r/ef1c54b2-97d4-4e57-bab9-6e196cdb5a8e","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ef1c54b2-97d4-4e57-bab9-6e196cdb5a8e_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/ef1c54b2-97d4-4e57-bab9-6e196cdb5a8e_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"PMID: 15542396: Sf9 insect cells transfected with the mutant show 10% wild-type enzymatic activity ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/138ba925-6006-45bb-8f70-5b5a18a25fcd","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/138ba925-6006-45bb-8f70-5b5a18a25fcd_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/138ba925-6006-45bb-8f70-5b5a18a25fcd_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"PMID: 15146460: CHO cells transfected with mutant show non-detectable enzymatic activity ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12}],"evidenceStrength":"Definitive","sequence":4817,"specifiedBy":"GeneValidityCriteria9","strengthScore":18,"subject":{"id":"https://genegraph.clinicalgenome.org/r/JjNvMOGG-So","type":"GeneValidityProposition","disease":"obo:MONDO_0009655","gene":"hgnc:10818","modeOfInheritance":"obo:HP_0000007"},"version":"1.1","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_438dab6d-abf4-44e8-a176-bb39ae128052-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}